Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03772210 · ClinicalTrials.gov registry record · NA

Mechanism and Dosimetry Exploration in TES Magnetic Resonance Current Mapping Methods

A NA study, sponsored by Arizona State University.

Completed
Registry status
NA
Development phase
123
Enrollment target

NCT03772210: Completed NA study, sponsored by Arizona State University.

NCT03772210 is a NA study that has completed, run by Arizona State University. The registered enrollment target is 123 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (91% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03772210, a NA study, has completed, sponsored by Arizona State University.

COMPLETED
Registry status
NA
Development phase
123 participants
Enrollment target

Study Summary

In this study the investigators will explore dosimetry in transcranial electrical stimulation using a novel magnetic resonance imaging technique that can determine how electrical stimulation distributes within the brain. The investigators will then combine this imaging technique with functional MR imaging to attempt mechanistic associations. If successful, the study outcomes will be an improved understanding of the interactions between electric current distributions and structures presumed to be targeted by stimulation.

Primary Outcome

MREIT data will be obtained multiple times for each subject

Interventions

  • OTHER Sham
  • DEVICE tDCS

Trial Details

FieldValue
Enrollment Target 123 participants
Start Date 2019-01-03
Est. Completion 2022-06-09
Phase NA
Arizona State University

187 total trials

What the finished NCT03772210 record still lists

NCT03772210 is an interventional study that assigns participants to a tested intervention. The registered 123 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (91% lower).

The record links to 0 conditions, and to 2 interventions - of which Sham is the first listed.

NCT03772210 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT03772210 about?

NCT03772210 is a clinical study titled "Mechanism and Dosimetry Exploration in TES Magnetic Resonance Current Mapping Methods". In this study the investigators will explore dosimetry in transcranial electrical stimulation using a novel magnetic resonance imaging technique that can determine how electrical stimulation distributes within the brain. The investigators will then combine this imaging technique with functional MR i...

What is the current status of trial NCT03772210?

This trial is currently completed. It is a NA study. The enrollment target is 123 participants. The study started on 2019-01-03. Estimated completion is 2022-06-09.

What interventions are being tested in trial NCT03772210?

The interventions under investigation include: Sham (OTHER), tDCS (DEVICE).

Who is sponsoring clinical trial NCT03772210?

This trial is sponsored by Arizona State University, which has 187 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT03772210's enrollment target sits among peer trials

123 762nd of 2000 higher than 1,239 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT05285891 · 123 participants · Phase 4

    Ocrelizumab Discontinuation in Relapsing Multiple Sclerosis

  • NCT05334368 · 123 participants · Phase 3

    Depemokimab in Participants With Hypereosinophilic Syndrome, Efficacy, and Safety Trial

  • NCT06088355 · 123 participants · NA

    Moderate Versus High Volume Light-Moderate Intensity Exercise for People With Moderate Parkinson's Disease

  • NCT06111131 · 123 participants · NA

    Ancora-SB Overtube Complete Positioning and Optical Visualization During Endoscopic Procedures

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT03772210, the US trial registry maintained by the National Library of Medicine. NCT03772210 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.